Ceribell
About Ceribell
Ceribell is a medical technology company dedicated to revolutionizing the diagnosis and management of patients with serious neurological conditions, particularly in acute care settings such as emergency departments and intensive care units. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform. This system combines proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, enabling rapid diagnosis and continuous monitoring of patients at risk for seizures.
For physicians, the Ceribell System offers a critical tool to address the limitations of traditional EEG technology, which can be time-consuming and resource-intensive. It provides clinically meaningful diagnostic information quickly, with the ability to detect non-convulsive status epilepticus (NCSE) within minutes, a condition often difficult to diagnose without visible signs of seizure. The AI-powered ‘Clarity’ algorithm provides instantaneous alerts for brain patterns consistent with seizures, allowing for real-time assessment of treatment effectiveness and improved patient outcomes. The system is FDA 510(k) cleared for indicating suspected seizure activity and is currently utilized in hundreds of hospitals across the U.S.
Focus Areas
Business Intelligence
| Key Investors | Ally Bridge Group, Longitude Capital, The Rise Fund, RA Capital Management, Redmile Group, Red Tree Venture Capital, Optimas Capital Partners, Horizon Technology Finance, UCB, LivaNova |
| Partnerships | UCB (Investor/Partner), LivaNova (Investor/Partner), Roxborough Memorial Hospital, Allegheny Health Network, Inspira Medical Centers, U.S. Department of Veterans Affairs |
| Technology | Ceribell System (proprietary, portable, rapidly deployable hardware including a disposable headband with integrated electrodes and a handheld recorder), AI-powered algorithms (Clarity, ClarityPro), cloud-based EEG Portal for remote review |
| FDA Clearances | 5 cleared products (estimated) |
What Physicians Need to Know
For physicians, Ceribell stands out by enabling rapid, objective neurological assessment at the point of care, significantly reducing diagnostic delays for critical conditions like seizures, ESE, delirium, and LVO stroke. The ease of use, requiring minimal training and no specialized EEG technicians for setup, means faster intervention and improved patient outcomes, including shorter hospital stays and reduced brain injury. The AI-powered real-time alerts and remote access to EEG data empower neurologists to make quicker, more confident treatment decisions from anywhere. Furthermore, its FDA clearances across multiple indications and for all age groups (from preterm neonates to adults) provide a versatile and reliable tool for diverse acute care settings. The disposable electrodes also enhance infection control.
Ceribell's system streams real-time EEG data to a HIPAA-compliant cloud-based portal, facilitating remote access and review by neurologists. This cloud integration is crucial for enabling rapid interpretation and collaborative decision-making, especially when specialized personnel are not immediately available on-site. The system is designed to integrate into existing clinical workflows in emergency departments and intensive care units, supporting faster triage and diagnosis without replacing standard clinical EEG or comprehensive neurological evaluation.
What the Web Says
Ceribell is a medical technology company that has developed an AI-powered point-of-care EEG system for rapid seizure detection and management in acute care settings. The product is generally well-received by healthcare providers for its ease of use and ability to expedite diagnoses, potentially reducing ICU stays and improving patient outcomes. However, there are mixed opinions regarding the accuracy of its AI, with some neurologists expressing concerns about false positives and its limitations compared to a full 18-channel EEG. As an employer, Ceribell receives mixed reviews, with some employees praising the product and team, while others highlight issues with company culture, management, and compensation.
Overall: MixedStrengths
- Game-changing product that is well-received by the market.
- Easy to use and apply, allowing for rapid assessment and treatment.
- Reduces diagnosis time for seizures and non-seizure conditions.
- Can lead to shorter ICU stays and improved neurological outcomes.
- Useful in settings without 24/7 in-house EEG technicians.
- Highly capable and motivated team.
Limitations
- AI aspects are not always impressive and can have high false positive rates.
- Does not replace a full montage EEG and has limitations in capturing all brain areas.
- Expensive single-use caps contribute to high running costs.
- Concerns about company culture, favoritism, and lack of trust among employees.
- Compensation may not be fairly evaluated based on job responsibilities, and bonuses can be minimal.
- Some employees felt that unnecessary roles were created, leading to frustration.
Based on reviews from: Indeed.com, Comparably, SimplyHired, FeaturedCustomers, TIME, Reddit (r/neurology, r/MedicalDevices), PMC (PubMed Central), Medical Device Network, Capterra, G2
Last updated: 2026-07-17
Videos
News, demos, and interviews about Ceribell.
Videos load interactively. If none appear, search YouTube for Ceribell →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Ceribell.
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]